← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

DarioHealth Corp. (DRIO) 10-Year Financial Performance & Capital Metrics

DRIO • • Industrial / General
HealthcareDiagnostics & ResearchDigital Health & Point-of-Care DiagnosticsDigital Therapeutics & Remote Monitoring
AboutDarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Show more
  • Revenue $27M +32.9%
  • EBITDA -$50M +1.7%
  • Net Income -$43M +28.1%
  • EPS (Diluted) -0.61 +68.4%
  • Gross Margin 49.06% +66.9%
  • EBITDA Margin -186.08% +26.0%
  • Operating Margin -213.55% +22.7%
  • Net Margin -158.09% +45.9%
  • ROE -65.68% +23.7%
  • ROIC -69.11% +10.2%
  • Debt/Equity 0.42 -17.5%
  • Interest Coverage -601.50 -590.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 29.0%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Expensive at 11.4x book value
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y87.26%
5Y29.04%
3Y9.65%
TTM7.29%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM28.43%

EPS CAGR

10Y-
5Y-
3Y-
TTM116.46%

ROCE

10Y Avg-226.25%
5Y Avg-88.57%
3Y Avg-61.4%
Latest-62.04%

Peer Comparison

Digital Therapeutics & Remote Monitoring
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
STIMNeuronetics, Inc.123.96M1.81-1.314.96%-34.27%-141.91%2.60
DRIODarioHealth Corp.82.59M12.22-20.0332.86%-137.17%-45.27%0.42

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+823K2.8M5.17M7.39M7.56M7.58M20.51M27.66M20.35M27.04M
Revenue Growth %15.14%2.41%0.84%0.43%0.02%0%1.71%0.35%-0.26%0.33%
Cost of Goods Sold+1.68M3.36M3.86M5.63M4.96M5.06M12.44M18M14.37M13.77M
COGS % of Revenue2.04%1.2%0.75%0.76%0.66%0.67%0.61%0.65%0.71%0.51%
Gross Profit+-855K-561K1.31M1.76M2.6M2.51M8.07M9.65M5.98M13.27M
Gross Margin %-1.04%-0.2%0.25%0.24%0.34%0.33%0.39%0.35%0.29%0.49%
Gross Profit Growth %0.62%0.34%3.34%0.35%0.47%-0.03%2.21%0.2%-0.38%1.22%
Operating Expenses+6.84M10.27M15.73M19.45M20.3M32.42M84.56M66.47M62.17M71.01M
OpEx % of Revenue8.31%3.66%3.04%2.63%2.69%4.28%4.12%2.4%3.05%2.63%
Selling, General & Admin4.28M8.12M12.43M15.78M16.61M27.98M62.36M46.82M41.8M46.83M
SG&A % of Revenue5.2%2.9%2.4%2.13%2.2%3.69%3.04%1.69%2.05%1.73%
Research & Development2.56M2.15M3.3M3.68M3.69M4.43M17.22M19.65M20.25M24.18M
R&D % of Revenue3.12%0.77%0.64%0.5%0.49%0.59%0.84%0.71%0.99%0.89%
Other Operating Expenses0000004.99M0128K0
Operating Income+-7.7M-11.1M-14.42M-17.69M-17.7M-29.9M-76.49M-56.81M-56.19M-57.74M
Operating Margin %-9.35%-3.96%-2.79%-2.39%-2.34%-3.95%-3.73%-2.05%-2.76%-2.14%
Operating Income Growth %0.32%-0.44%-0.3%-0.23%-0%-0.69%-1.56%0.26%0.01%-0.03%
EBITDA+-7.36M-10.71M-14.22M-17.48M-17.52M-29.71M-72.04M-52.09M-51.2M-50.32M
EBITDA Margin %-8.95%-3.82%-2.75%-2.36%-2.32%-3.92%-3.51%-1.88%-2.52%-1.86%
EBITDA Growth %0.32%-0.46%-0.33%-0.23%-0%-0.7%-1.42%0.28%0.02%0.02%
D&A (Non-Cash Add-back)335K387K195K207K183K190K4.46M4.72M4.99M7.43M
EBIT-7.7M-10.83M-14.42M-17.69M-17.7M-29.9M-74.47M-60.31M-59.36M-57.74M
Net Interest Income+-22K-20K-171K-18K-11K12K-40K-2.18M1.22M1.02M
Interest Income000016K61K44K506K1.87M1.12M
Interest Expense22K20K171K18K27K49K84K2.68M645K96K
Other Income/Expense556K214K-1.32M-115K-31K458K-235K-5.38M-3.17M13.14M
Pretax Income+-7.14M-10.89M-15.74M-17.8M-17.74M-29.45M-76.73M-62.19M-59.36M-44.6M
Pretax Margin %-8.68%-3.88%-3.05%-2.41%-2.35%-3.89%-3.74%-2.25%-2.92%-1.65%
Income Tax+055K0-115K0032K4K64K-1.85M
Effective Tax Rate %1%1%1%1%1%1%1%1%1%0.96%
Net Income+-7.14M-10.89M-15.74M-17.8M-17.74M-29.45M-76.76M-62.19M-59.43M-42.75M
Net Margin %-8.68%-3.88%-3.05%-2.41%-2.35%-3.89%-3.74%-2.25%-2.92%-1.58%
Net Income Growth %0.45%-0.52%-0.45%-0.13%0%-0.66%-1.61%0.19%0.04%0.28%
Net Income (Continuing)-7.14M-10.89M-15.74M-17.8M-17.74M-29.45M-76.76M-62.19M-59.43M-42.75M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-75.27-41.85-32.70-15.21-7.84-5.55-4.63-2.63-1.93-0.61
EPS Growth %0.86%0.44%0.22%0.53%0.48%0.29%0.17%0.43%0.27%0.68%
EPS (Basic)-75.27-41.85-32.70-15.21-7.84-5.55-4.63-2.63-1.930.61
Diluted Shares Outstanding94.89K260.15K481.41K1.17M2.27M5.96M16.59M23.64M28.37M67.18M
Basic Shares Outstanding94.89K260.15K481.41K1.17M2.27M5.96M16.59M23.64M28.37M67.18M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+4.29M2.94M6.05M13.31M22.91M34.13M45.6M65.52M47.33M40.53M
Cash & Short-Term Investments2.75M1.32M3.98M11M20.59M28.59M36M49.36M36.8M28.46M
Cash Only2.67M1.09M3.72M11M20.59M28.59M36M49.36M36.8M27.76M
Short-Term Investments80K225K258K000000697K
Accounts Receivable22K290K435K234K712K1.7M1.79M6.42M3.64M5.35M
Days Sales Outstanding9.7637.7630.7111.5534.3882.131.7884.6865.3372.24
Inventory601K888K1.18M1.38M1.41M2.29M6.23M7.96M5.06M4.75M
Days Inventory Outstanding130.7396.35111.9989.29104.01165.31182.68161.32128.59125.96
Other Current Assets291K0258K251K0187K0887K292K175K
Total Non-Current Assets+790K936K911K776K1.65M1.28M55.17M53.67M49.06M78.36M
Property, Plant & Equipment749K901K869K733K1.41M1.07M989K1.99M1.87M1.77M
Fixed Asset Turnover1.10x3.11x5.95x10.09x5.35x7.05x20.74x13.87x10.91x15.24x
Goodwill00000041.64M41.64M41.64M57.43M
Intangible Assets00000012.46M9.92M5.4M18.76M
Long-Term Investments41K35K42K43K17K020K6K6K0
Other Non-Current Assets0000224K205K57K117K143K392K
Total Assets+5.08M3.87M6.96M14.09M24.57M35.41M100.77M119.19M96.39M118.88M
Asset Turnover0.16x0.72x0.74x0.52x0.31x0.21x0.20x0.23x0.21x0.23x
Asset Growth %0.65%-0.24%0.8%1.03%0.74%0.44%1.85%0.18%-0.19%0.23%
Total Current Liabilities+1.69M2.92M3.02M5.16M5.22M7.03M14.38M19.35M12.49M16.64M
Accounts Payable978K1.81M1.85M2.57M1.66M2.48M5.11M2.32M1.13M3.04M
Days Payables Outstanding212.74196.61175.17166.91121.81178.79149.8547.0828.7380.7
Short-Term Debt0000317K0266K8.82M3.95M5.45M
Deferred Revenue (Current)31K00736K1000K1000K1000K1000K997K1000K
Other Current Liabilities434K00880K887K880K4.4M2.19M4.07M0
Current Ratio2.54x1.00x2.01x2.58x4.39x4.85x3.17x3.39x3.79x2.44x
Quick Ratio2.18x0.70x1.61x2.31x4.12x4.53x2.74x2.98x3.38x2.15x
Cash Conversion Cycle-72.25-62.49-32.47-66.0716.5868.6164.6198.92165.2117.51
Total Non-Current Liabilities+2.61M7.49M1K0455K222K846K19.84M25.75M30.23M
Long-Term Debt000000018.11M24.59M23.47M
Capital Lease Obligations0000455K222K21K827K885K765K
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities2.61M7.49M1K000825K910K276K5.99M
Total Liabilities4.3M10.41M3.02M5.16M5.67M7.26M15.22M39.19M38.24M46.87M
Total Debt+2.36M000772K532K287K28.05M29.54M30.19M
Net Debt-314K-1.09M-3.72M-11M-19.81M-28.06M-35.71M-21.31M-7.26M2.43M
Debt / Equity3.03x---0.04x0.02x0.00x0.35x0.51x0.42x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-349.91x-555.05x-84.32x-982.67x-655.74x-610.27x-910.64x-21.17x-87.11x-601.50x
Total Equity+777K-6.54M3.94M8.93M18.89M28.15M85.55M80M58.14M72.02M
Equity Growth %1.31%-9.42%1.6%1.26%1.12%0.49%2.04%-0.06%-0.27%0.24%
Book Value per Share8.19-25.148.197.628.344.725.163.382.051.07
Total Shareholders' Equity777K-6.54M3.94M8.93M18.89M28.15M85.55M80M58.14M72.02M
Common Stock5K6K7K8K002K3K3K4K
Retained Earnings-43.35M-54.96M-70.96M-89.25M-110.14M-143.25M-222.01M-285.85M-349.36M-390.34M
Treasury Stock0000000000
Accumulated OCI-432K-286K-477K-440K000000
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-6.28M-8.38M-10.62M-11.47M-15.72M-17.74M-50.41M-47.84M-30.38M-38.56M
Operating CF Margin %-7.63%-2.99%-2.05%-1.55%-2.08%-2.34%-2.46%-1.73%-1.49%-1.43%
Operating CF Growth %0.27%-0.33%-0.27%-0.08%-0.37%-0.13%-1.84%0.05%0.37%-0.27%
Net Income-7.14M-10.89M-15.74M-17.8M-17.74M-29.45M-76.76M-62.19M-59.43M-42.75M
Depreciation & Amortization335K387K195K207K183K457K4.46M4.72M4.99M7.43M
Stock-Based Compensation1.72M1.04M3.82M3.76M2.26M024.97M16.98M19.7M15.8M
Deferred Taxes0000-4.69M00000
Other Non-Cash Items-579K9K1.18M-1K4.69M11.1M-503K3.56M288K-16.57M
Working Capital Changes-614K1.07M-77K2.37M-429K150K-2.57M-10.9M4.07M-2.47M
Change in Receivables-649K-226K-56K114K-504K-604K-367K-5.11M2.83M1.6M
Change in Inventory-366K-287K-295K-193K-37K-879K-2.23M-1.73M2.89M308K
Change in Payables292K834K39K722K-918K824K1.08M-2.79M-1.19M-496K
Cash from Investing+-113K-947K-219K6K-113K-1.62M-8.13M-573K-547K-8.93M
Capital Expenditures-110K-808K-195K-71K-98K-118K-261K-442K-584K-138K
CapEx % of Revenue0.13%0.29%0.04%0.01%0.01%0.02%0.01%0.02%0.03%0.01%
Acquisitions----------
Investments----------
Other Investing-6K6K-7K-1K0-1.5M-400K-131K00
Cash from Financing+7.61M7.75M13.46M18.74M25.25M27.55M65.77M61.94M18.25M38.53M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing533K210K0000889K000
Net Change in Cash----------
Free Cash Flow+-6.39M-9.19M-10.81M-11.54M-15.82M-17.85M-50.67M-48.42M-30.96M-38.7M
FCF Margin %-7.76%-3.28%-2.09%-1.56%-2.09%-2.36%-2.47%-1.75%-1.52%-1.43%
FCF Growth %0.3%-0.44%-0.18%-0.07%-0.37%-0.13%-1.84%0.04%0.36%-0.25%
FCF per Share-67.31-35.31-22.46-9.86-6.98-2.99-3.05-2.05-1.09-0.58
FCF Conversion (FCF/Net Income)0.88x0.77x0.67x0.64x0.89x0.60x0.66x0.77x0.51x0.90x
Interest Paid00000001.88M4.03M3.93M
Taxes Paid0000000000

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-919.18%--399.47%-276.74%-127.51%-125.18%-135.02%-75.14%-86.04%-65.68%
Return on Invested Capital (ROIC)-------229.81%-78.52%-76.92%-69.11%
Gross Margin-103.89%-20.01%25.36%23.87%34.36%33.17%39.34%34.91%29.4%49.06%
Net Margin-867.8%-388.41%-304.51%-240.78%-234.63%-388.66%-374.21%-224.88%-292%-158.09%
Debt / Equity3.03x---0.04x0.02x0.00x0.35x0.51x0.42x
Interest Coverage-349.91x-555.05x-84.32x-982.67x-655.74x-610.27x-910.64x-21.17x-87.11x-601.50x
FCF Conversion0.88x0.77x0.67x0.64x0.89x0.60x0.66x0.77x0.51x0.90x
Revenue Growth1513.73%240.58%84.45%43.02%2.23%0.22%170.76%34.82%-26.41%32.86%

Revenue by Segment

201920202021202220232024
Service2.07M1.81M---20.2M
Service Growth--12.57%----
Services--2.72M17.86M13.08M-
Services Growth---556.58%-26.74%-
Consumers---11.28M8.29M-
Consumers Growth-----26.47%-
Commercial---16.38M--
Commercial Growth------
Products--17.79M---
Products Growth------
Product5.49M5.77M----
Product Growth-5.05%----
Consumer Products And Other Revenues4.48M4.39M----
Consumer Products And Other Revenues Growth--1.92%----
Membership2.93M3.18M----
Membership Growth-8.67%----

Frequently Asked Questions

Growth & Financials

DarioHealth Corp. (DRIO) reported $24.7M in revenue for fiscal year 2024.

DarioHealth Corp. (DRIO) grew revenue by 32.9% over the past year. This is strong growth.

DarioHealth Corp. (DRIO) reported a net loss of $33.9M for fiscal year 2024.

Dividend & Returns

DarioHealth Corp. (DRIO) has a return on equity (ROE) of -65.7%. Negative ROE indicates the company is unprofitable.

DarioHealth Corp. (DRIO) had negative free cash flow of $26.9M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.